Small-Cell Lung Cancer – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Small-Cell Lung Cancer – Pipeline Review, H2 2017’, provides an overview of the Small-Cell Lung Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Small-Cell Lung Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Small-Cell Lung Cancer and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Small-Cell Lung Cancer

The report reviews pipeline therapeutics for Small-Cell Lung Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Small-Cell Lung Cancer therapeutics and enlists all their major and minor projects

The report assesses Small-Cell Lung Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Small-Cell Lung Cancer

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Small-Cell Lung Cancer

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Small-Cell Lung Cancer pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

A. Menarini Industrie Farmaceutiche Riunite Srl

AbbVie Inc

Advanced Accelerator Applications SA

Advantagene Inc

Advenchen Laboratories LLC

Aeglea BioTherapeutics Inc

Alchemia Ltd

Amgen Inc

Andarix Pharmaceuticals Inc

Aposense Ltd

Aprea AB

Ascentage Pharma Group Corp Ltd

Astellas Pharma Inc

Astex Pharmaceuticals Inc

AstraZeneca Plc

AVEO Pharmaceuticals Inc

Bayer AG

BeiGene Ltd

Beta Pharma Inc

BioLineRx Ltd

Bionomics Ltd

Bristol-Myers Squibb Co

Celgene Corp

Celldex Therapeutics Inc

Checkpoint Therapeutics Inc

Chipscreen Biosciences Ltd

Critical Outcome Technologies Inc

Double Bond Pharmaceutical International AB

Eli Lilly and Co

F. Hoffmann-La Roche Ltd

G1 Therapeutics Inc

Genzyme Corp

GlaxoSmithKline Plc

Horizon Pharma Plc

Immunomedics Inc

Incyte Corp

Innovation Pharmaceuticals Inc

Ipsen SA

Johnson & Johnson

Karyopharm Therapeutics Inc

Lindis Biotech GmbH

MabVax Therapeutics Holdings Inc

Madrigal Pharmaceuticals Inc.

MedImmune LLC

Merck & Co Inc

Merck KGaA

Merrimack Pharmaceuticals Inc

Mirati Therapeutics Inc

Moderna Therapeutics Inc

MolMed SpA

Mologen AG

Mundipharma International Ltd

Nektar Therapeutics

NewLink Genetics Corp

Nippon Kayaku Co Ltd

Novartis AG

Ono Pharmaceutical Co Ltd

Pfizer Inc

Pharma Mar SA

Plexxikon Inc

Polaris Pharmaceuticals Inc

Rafael Pharmaceuticals Inc

Recombio SL

Rexahn Pharmaceuticals Inc

Sun Pharma Advanced Research Company Ltd

Sunshine Biopharma Inc

Syros Pharmaceuticals Inc

Takeda Pharmaceutical Co Ltd

Tarveda Therapeutics Inc

Tesaro Inc

Teva Pharmaceutical Industries Ltd

Trovagene Inc

United Therapeutics Corp

Verastem Inc

ViiV Healthcare UK Ltd

Xencor Inc

Table of Contents

Table of Contents

Table of Contents 2

Introduction 6

Small-Cell Lung Cancer - Overview 7

Small-Cell Lung Cancer - Therapeutics Development 8

Small-Cell Lung Cancer - Therapeutics Assessment 25

Small-Cell Lung Cancer - Companies Involved in Therapeutics Development 39

Small-Cell Lung Cancer - Drug Profiles 76

Small-Cell Lung Cancer - Dormant Projects 714

Small-Cell Lung Cancer - Discontinued Products 720

Small-Cell Lung Cancer - Product Development Milestones 722

Appendix 741

List of Tables

List of Tables

Number of Products under Development for Small-Cell Lung Cancer, H2 2017 22

Number of Products under Development by Companies, H2 2017 24

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017 25

Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017 26

Number of Products under Development by Companies, H2 2017 (Contd..3), H2 2017 27

Number of Products under Development by Companies, H2 2017 (Contd..4), H2 2017 28

Number of Products under Development by Universities/Institutes, H2 2017 29

Products under Development by Companies, H2 2017 30

Products under Development by Companies, H2 2017 (Contd..1), H2 2017 31

Products under Development by Companies, H2 2017 (Contd..2), H2 2017 32

Products under Development by Companies, H2 2017 (Contd..3), H2 2017 33

Products under Development by Companies, H2 2017 (Contd..4), H2 2017 34

Products under Development by Companies, H2 2017 (Contd..5), H2 2017 35

Products under Development by Companies, H2 2017 (Contd..6), H2 2017 36

Products under Development by Companies, H2 2017 (Contd..7), H2 2017 37

Products under Development by Universities/Institutes, H2 2017 38

Number of Products by Stage and Target, H2 2017 40

Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017 41

Number of Products by Stage and Target, H2 2017 (Contd..2), H2 2017 42

Number of Products by Stage and Target, H2 2017 (Contd..3), H2 2017 43

Number of Products by Stage and Mechanism of Action, H2 2017 45

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017 46

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..2), H2 2017 47

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..3), H2 2017 48

Number of Products by Stage and Route of Administration, H2 2017 50

Number of Products by Stage and Molecule Type, H2 2017 52

Small-Cell Lung Cancer – Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H2 2017 53

Small-Cell Lung Cancer – Pipeline by AbbVie Inc, H2 2017 54

Small-Cell Lung Cancer – Pipeline by Advanced Accelerator Applications SA, H2 2017 54

Small-Cell Lung Cancer – Pipeline by Advantagene Inc, H2 2017 55

Small-Cell Lung Cancer – Pipeline by Advenchen Laboratories LLC, H2 2017 55

Small-Cell Lung Cancer – Pipeline by Aeglea BioTherapeutics Inc, H2 2017 55

Small-Cell Lung Cancer – Pipeline by Alchemia Ltd, H2 2017 56

Small-Cell Lung Cancer – Pipeline by Amgen Inc, H2 2017 56

Small-Cell Lung Cancer – Pipeline by Andarix Pharmaceuticals Inc, H2 2017 57

Small-Cell Lung Cancer – Pipeline by Aposense Ltd, H2 2017 57

Small-Cell Lung Cancer – Pipeline by Aprea AB, H2 2017 58

Small-Cell Lung Cancer – Pipeline by Ascentage Pharma Group Corp Ltd, H2 2017 58

Small-Cell Lung Cancer – Pipeline by Astellas Pharma Inc, H2 2017 58

Small-Cell Lung Cancer – Pipeline by Astex Pharmaceuticals Inc, H2 2017 59

Small-Cell Lung Cancer – Pipeline by AstraZeneca Plc, H2 2017 59

Small-Cell Lung Cancer – Pipeline by AVEO Pharmaceuticals Inc, H2 2017 60

Small-Cell Lung Cancer – Pipeline by Bayer AG, H2 2017 61

Small-Cell Lung Cancer – Pipeline by BeiGene Ltd, H2 2017 61

Small-Cell Lung Cancer – Pipeline by Beta Pharma Inc, H2 2017 61

Small-Cell Lung Cancer – Pipeline by BioLineRx Ltd, H2 2017 62

Small-Cell Lung Cancer – Pipeline by Bionomics Ltd, H2 2017 62

Small-Cell Lung Cancer – Pipeline by Bristol-Myers Squibb Co, H2 2017 63

Small-Cell Lung Cancer – Pipeline by Celgene Corp, H2 2017 64

Small-Cell Lung Cancer – Pipeline by Celldex Therapeutics Inc, H2 2017 64

Small-Cell Lung Cancer – Pipeline by Checkpoint Therapeutics Inc, H2 2017 65

Small-Cell Lung Cancer – Pipeline by Chipscreen Biosciences Ltd, H2 2017 65

Small-Cell Lung Cancer – Pipeline by Critical Outcome Technologies Inc, H2 2017 66

Small-Cell Lung Cancer – Pipeline by Double Bond Pharmaceutical International AB, H2 2017 66

Small-Cell Lung Cancer – Pipeline by Eli Lilly and Co, H2 2017 67

Small-Cell Lung Cancer – Pipeline by F. Hoffmann-La Roche Ltd, H2 2017 67

Small-Cell Lung Cancer – Pipeline by G1 Therapeutics Inc, H2 2017 68

Small-Cell Lung Cancer – Pipeline by Genzyme Corp, H2 2017 68

Small-Cell Lung Cancer – Pipeline by GlaxoSmithKline Plc, H2 2017 69

Small-Cell Lung Cancer – Pipeline by Horizon Pharma Plc, H2 2017 69

Small-Cell Lung Cancer – Pipeline by Immunomedics Inc, H2 2017 70

Small-Cell Lung Cancer – Pipeline by Incyte Corp, H2 2017 70

Small-Cell Lung Cancer – Pipeline by Innovation Pharmaceuticals Inc, H2 2017 71

Small-Cell Lung Cancer – Pipeline by Ipsen SA, H2 2017 71

Small-Cell Lung Cancer – Pipeline by Johnson & Johnson, H2 2017 72

Small-Cell Lung Cancer – Pipeline by Karyopharm Therapeutics Inc, H2 2017 72

Small-Cell Lung Cancer – Pipeline by Lindis Biotech GmbH, H2 2017 72

Small-Cell Lung Cancer – Pipeline by MabVax Therapeutics Holdings Inc, H2 2017 73

Small-Cell Lung Cancer – Pipeline by Madrigal Pharmaceuticals Inc., H2 2017 73

Small-Cell Lung Cancer – Pipeline by MedImmune LLC, H2 2017 74

Small-Cell Lung Cancer – Pipeline by Merck & Co Inc, H2 2017 75

Small-Cell Lung Cancer – Pipeline by Merck KGaA, H2 2017 75

Small-Cell Lung Cancer – Pipeline by Merrimack Pharmaceuticals Inc, H2 2017 76

Small-Cell Lung Cancer – Pipeline by Mirati Therapeutics Inc, H2 2017 76

Small-Cell Lung Cancer – Pipeline by Moderna Therapeutics Inc, H2 2017 77

Small-Cell Lung Cancer – Pipeline by MolMed SpA, H2 2017 77

Small-Cell Lung Cancer – Pipeline by Mologen AG, H2 2017 78

Small-Cell Lung Cancer – Pipeline by Mundipharma International Ltd, H2 2017 78

Small-Cell Lung Cancer – Pipeline by Nektar Therapeutics, H2 2017 78

Small-Cell Lung Cancer – Pipeline by NewLink Genetics Corp, H2 2017 79

Small-Cell Lung Cancer – Pipeline by Nippon Kayaku Co Ltd, H2 2017 79

Small-Cell Lung Cancer – Pipeline by Novartis AG, H2 2017 80

Small-Cell Lung Cancer – Pipeline by Ono Pharmaceutical Co Ltd, H2 2017 81

Small-Cell Lung Cancer – Pipeline by Pfizer Inc, H2 2017 81

Small-Cell Lung Cancer – Pipeline by Pharma Mar SA, H2 2017 82

Small-Cell Lung Cancer – Pipeline by Plexxikon Inc, H2 2017 82

Small-Cell Lung Cancer – Pipeline by Polaris Pharmaceuticals Inc, H2 2017 82

Small-Cell Lung Cancer – Pipeline by Rafael Pharmaceuticals Inc, H2 2017 83

Small-Cell Lung Cancer – Pipeline by Recombio SL, H2 2017 83

Small-Cell Lung Cancer – Pipeline by Rexahn Pharmaceuticals Inc, H2 2017 84

Small-Cell Lung Cancer – Pipeline by Sun Pharma Advanced Research Company Ltd, H2 2017 84

Small-Cell Lung Cancer – Pipeline by Sunshine Biopharma Inc, H2 2017 85

Small-Cell Lung Cancer – Pipeline by Syros Pharmaceuticals Inc, H2 2017 85

Small-Cell Lung Cancer – Pipeline by Takeda Pharmaceutical Co Ltd, H2 2017 86

Small-Cell Lung Cancer – Pipeline by Tarveda Therapeutics Inc, H2 2017 86

Small-Cell Lung Cancer – Pipeline by Tesaro Inc, H2 2017 86

Small-Cell Lung Cancer – Pipeline by Teva Pharmaceutical Industries Ltd, H2 2017 87

Small-Cell Lung Cancer – Pipeline by Trovagene Inc, H2 2017 87

Small-Cell Lung Cancer – Pipeline by United Therapeutics Corp, H2 2017 88

Small-Cell Lung Cancer – Pipeline by Verastem Inc, H2 2017 88

Small-Cell Lung Cancer – Pipeline by ViiV Healthcare UK Ltd, H2 2017 89

Small-Cell Lung Cancer – Pipeline by Xencor Inc, H2 2017 89

Small-Cell Lung Cancer – Dormant Projects, H2 2017 728

Small-Cell Lung Cancer – Dormant Projects, H2 2017 (Contd..1), H2 2017 729

Small-Cell Lung Cancer – Dormant Projects, H2 2017 (Contd..2), H2 2017 730

Small-Cell Lung Cancer – Dormant Projects, H2 2017 (Contd..3), H2 2017 731

Small-Cell Lung Cancer – Dormant Projects, H2 2017 (Contd..4), H2 2017 732

Small-Cell Lung Cancer – Dormant Projects, H2 2017 (Contd..5), H2 2017 733

Small-Cell Lung Cancer – Discontinued Products, H2 2017 734

Small-Cell Lung Cancer – Discontinued Products, H2 2017 (Contd..1), H2 2017 735

List of Figures

List of Figures

Number of Products under Development for Small-Cell Lung Cancer, H2 2017 22

Number of Products under Development by Companies, H2 2017 23

Number of Products under Development by Universities/Institutes, H2 2017 29

Number of Products by Top 10 Targets, H2 2017 39

Number of Products by Stage and Top 10 Targets, H2 2017 39

Number of Products by Top 10 Mechanism of Actions, H2 2017 44

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017 44

Number of Products by Routes of Administration, H2 2017 49

Number of Products by Stage and Routes of Administration, H2 2017 49

Number of Products by Top 10 Molecule Types, H2 2017 51

Number of Products by Stage and Top 10 Molecule Types, H2 2017 51

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports